Methods and compositions for treatment of ocular disorders and blinding diseases

Patent metadata

Field	Value
Publication number	US-12097267-B2
Application number	US-202017099421-A
Country	US
Kind code	B2
Filing date	Nov 16, 2020
Priority date	Jan 5, 2016
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

Codon optimized nucleic acid sequences for the long form and short form of RdCVF are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequences. Recombinant vectors are provided that express the codon optimized RdCVFL and RdCVF individually, or express two copies of a codon optimized RdCVF or RdCVFL nucleic acid sequence, or both RdCVFL and RdCVF in a single vector or virus. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence or inappropriate expression of RdCVF and RdCVFL.

First claim

The invention claimed is:

1. An expression cassette comprising:
(a) the nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1,
(b) the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2,
(c) the nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1 and the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2, or
(d) two copies of the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2,
wherein the nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1 encodes RdCVFL and the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2 encodes RdCVF.

2. The expression cassette of claim 1 , wherein each nucleic acid sequence is operatively associated with an expression control sequence that directs expression of RdCVFL or RdCVF in a host cell.

3. A plasmid comprising the expression cassette of claim 1 .

4. An isolated host cell comprising the plasmid of claim 3 .

5. A recombinant AAV (rAAV) vector comprising a genome comprising AAV inverted terminal repeat sequences flanking the expression cassette of claim 1 .

6. An rAAV vector comprising a genome comprising AAV inverted terminal repeat sequences and an expression cassette comprising the nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1 or in nucleotides 13 to 339 SEQ ID NO: 2 and expression control sequences that direct expression of the nucleic acid sequence in a host cell.

7. The rAAV vector of claim 6 , wherein the genome comprises a 5′ AAV inverted terminal repeat sequence, a first CMV/CBA promoter, a first nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1 or in nucleotides 13 to 339 SEQ ID NO: 2, a first polyadenylation sequence, transcriptional terminator sequences, a second CMV/CBA promoter, a second nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1 or in nucleotides 13 to 339 SEQ ID NO: 2, a second polyadenylation sequence, and a 3′ AAV inverted terminal repeat sequence.

8. A composition comprising a pharmaceutically acceptable carrier suitable for delivery to the eye and the rAAV vector of claim 6 .

9. A composition comprising a nucleic acid molecule useful in the treatment of an ocular disease, the composition comprising:
a) the nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1,
(b) the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2,
(c) the nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1 and the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2, or
(d) two copies of the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2,
wherein the nucleic acid sequence set forth in nucleotides 20 to 655 of SEQ ID NO: 1 encodes RdCVFL and the nucleic acid sequence set forth in nucleotides 13 to 339 of SEQ ID NO: 2 encodes RdCVF, and
wherein the nucleic acid sequence encoding RdCVFL and/or the nucleic acid sequence encoding RdCVF is under the control of expression control sequences that direct expression of the encoded RdCVFL and/or RdCVF in ocular cells; and a carrier suitable for delivery to the eye of a subject.

Assignees

• Univ Pennsylvania

Inventors

• Bennicelli Jeannette
• Bennett Jean
• Sun Junwei

Classifications

• C12N2830/001

  controllable enhancer/promoter combination · CPC title

• C12N2800/22

  Vectors comprising a coding region that has been codon optimised for expression in a respective host · CPC title

• C12N9/0051

  acting on a sulfur group of donors (1.8) · CPC title

• A61K48/0075

  characterised by an aspect of the delivery route, e.g. oral, subcutaneous · CPC title

• A61K38/44

  Oxidoreductases (1) · CPC title